Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): study protocol for a phase 3, pan-European, two-group, non-commercial, active-control, observer-masked, superiority, randomised controlled surgical trial.
Trials
; 23(1): 99, 2022 Jan 31.
Article
em En
| MEDLINE
| ID: mdl-35101110
Palavras-chave
Aflibercept; Alteplase; Anti-vascular endothelial growth factor (anti-VEGF); Cost-effectiveness; Economic analysis; Gas tamponade; Neovascular age-related macular degeneration; Pars plana vitrectomy; Quality-adjusted life year (QALY); Randomised controlled trial; Submacular haemorrhage; Surgery; Tissue plasminogen activator
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Ativador de Plasminogênio Tecidual
/
Degeneração Macular Exsudativa
Tipo de estudo:
Clinical_trials
/
Diagnostic_studies
/
Etiology_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article